Dr Reddys Laboratories Ltd Q4 FY2023 Concall Summary

Key Takeaways

• All-time-high FY23, but Q4 margin slipped: FY23 delivered record sales, profits and cash flow with double-digit top and bottom line growth, yet Q4 gross margin fell 210 bps QoQ on product mix and lower operating leverage.
• U.S. growth story rests on launch volume, not just gRevlimid: North America grew 26% in FY23, and management expects to launch 25 to 30 products in FY24, targeting less-competitive spaces to sustain growth even as price erosion persists.
• India is the standout, and innovation access is the moat: India grew 32% in Q4, and management is confident of beating IPM growth by leveraging international partnerships to bring novel assets into the country.
• The 25-25 margin framework is a long-term anchor, not a floor: Management reaffirmed the 25% EBITDA and 25% ROCE target but warned that quarters above and below will occur as extra results are reinvested, including 50-100 bps into Horizon 2 innovation.
• What to watch next quarter: Whether the 25-30 U.S. launch target begins converting into revenue, the pace of PSAI's promised return to double-digit growth, and any quantification of the Mayne portfolio contribution.

U.S. Business: Launches, Price Erosion and the gRevlimid Overhang

• Launch volume as the growth engine: Management expects to launch 25 to 30 products in the U.S. during FY24, including contributions from the Mayne and Eton acquisitions, and believes this volume alone can drive growth.
• Strategy targets less-competitive products: The focus is on products with fewer competitors, and management intends to keep accumulating such assets in FY24 and beyond. The Mayne portfolio, strong in women's health, fits this thesis and carries a pipeline of unlaunched products.
• Price erosion is structural, not gone: The nature of the U.S. market did not change; Q4's lower erosion was a function of product mix, not a market shift. Both injectables and oral solids remain very competitive, and erosion will return when competition hits specific products.
• gRevlimid is meaningful but lumpy: Lenalidomide is expected to remain a meaningful product for the entire agreement timeline, but quarter-to-quarter fluctuations are purely ordering patterns within a limited-volume arrangement. Management declined to share quantity numbers or a sustainability run rate.
• Base business growth disputed: An analyst observed that ex-Revlimid U.S. growth looked low; management rejected the observation and stated they expect continued growth in all spaces, with and without the product.

Israeli: "I believe that we will grow not just because of the product. We will grow because we are also launching 25 to 30 products. And the combination of all that mix should grow up in the United"

India & Emerging Markets: The Innovation Access Play

• India delivered 32% Q4 growth: Excluding divestment income and COVID products, growth was still a healthy 11% in Q4 and 13% for the full year. Management is confident of beating IPM growth in FY24 and beyond.
• Innovation partnerships are the differentiator: Dr. Reddy's is positioning itself as the partner of choice for international innovators (U.S., Israel, China) seeking compliant, reputable entry into India. Recent Horizon 2 deals include wearables for atrial fibrillation and migraine, a third-generation CAR T asset, and Toripalimab.
• Bottom-line focus over market-share optics: Management emphasized that bottom-line growth matters more than IQVIA-reported market share, and they expect India's bottom line to grow faster than the top line.
• Russia decline is timing, not structural: The YoY decline reflects a high base from Q4 FY22 upstocking when the conflict began; the sequential decline is tender timing for biologic products. Business is described as usual.
• ROW markets returning to traditional growth: Ex-Russia, management is targeting the historical north-of-20% growth range, driven by accelerated development, filings, and hospital business footprint expansion.

Israeli: "And our path of growth is people see us as a very attractive partner being compliant with all the international norms, given our reputation in the marketplace, and we are leveraging it to bring more and more innovation into India."

Margin Dynamics: Product Mix, Investment and the 25-25 Framework

• Q4 gross margin fell 210 bps QoQ: The decline was driven by product mix and lower operating leverage, partly offset by divestment income. For the full year, gross margin rose 360 bps on new product sales, government incentives and favourable forex.
• SG&A rose on sales investment and forex: The YoY increase was largely attributable to sales and marketing investments and adverse forex translation impact.
• 25-25 is a long-term anchor, not a quarterly promise: Management reaffirmed the 25% EBITDA and 25% ROCE target but explicitly stated there will be years and quarters above and possibly below. Extra performance is being allocated to investment.
• Horizon 2 investment sits inside the framework: 50 to 100 bps of margin is allocated to Horizon 2 innovation initiatives, financed within the 25-25 envelope.
• Core margin debate: An analyst suggested core EBITDA margin (stripping one-offs) looked lower than earlier guidance; management rejected the observation.

Geographic & Segment Performance

Pipeline, Partnerships & Inorganic Moves

• Biosimilar milestones advancing: Fresenius Kabi launched Stimufend (Pegfilgrastim) in the U.S.; Rituximab biosimilars filed in the U.S., Europe and UK; Phase 1 completed for tocilizumab biosimilar; global Phase 3 initiated on another asset.
• China approvals gaining traction: Three product approvals received (Sevelamer, Sitagliptin, Carboprost) plus a partner GEA approval. Management is very pleased with early market entry and expects bigger revenue impact in FY25 and FY26 as submissions, approvals and GPO timing play out.
• Mayne portfolio fills a gap: The acquired U.S. generic prescription portfolio is strong in women's health, an area Dr. Reddy's was missing. The pipeline of unlaunched products and relatively attractive deal economics support growth ambitions.
• M&A appetite remains open: Management is open to acquisitions across licensing, product acquisitions, collaborations and M&A, with a continued focus on U.S. opportunities both organic and inorganic. Nothing reportable at this stage.
• CTO-1 observation received: A minor U.S. FDA observation was received; the response will be submitted within the 15-day window.

Guidance & Commitments

Key Metrics